Related Experiment Video
Updated: Aug 14, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
RASAL2 Deficiency Attenuates Hepatic Steatosis by Promoting Hepatic VLDL Secretion via the AKT/TET1/MTTP Axis
Hao Ding1, Jiang-Hong Yu1,2, Ge Ge3
1Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Journal of Clinical and Translational Hepatology
|January 16, 2023
Summary
RASAL2 deficiency improves fatty liver by regulating lipid metabolism. This involves the AKT/TET1/MTTP pathway, offering a new target for nonalcoholic fatty liver disease (NAFLD) treatment.
Area of Science:
- Metabolic regulation
- Liver disease research
- Lipid metabolism
Background:
- RASAL2 (RAS protein activator like 2) is a metabolic regulator.
- Its role in hepatic lipid metabolism and NAFLD is unknown.
Purpose of the Study:
- Investigate RASAL2 function in NAFLD.
- Elucidate mechanisms of RASAL2 in hepatic lipid metabolism.
Main Methods:
- Established NAFLD models (high-fat diet, free fatty acids).
- Assessed steatosis, lipid accumulation, and VLDL secretion.
- Analyzed gene regulation via ChIP and hMeDIP-qPCR.
Main Results:
- RASAL2 deficiency ameliorated hepatic steatosis.
- Upregulated TET1 via AKT pathway, promoting MTTP expression.
- Increased VLDL production and secretion.
Conclusions:
- RASAL2 deficiency alleviates NAFLD via AKT/TET1/MTTP axis.
- Highlights RASAL2 as a potential therapeutic target for NAFLD.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
3.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.8K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K